IFN Signaling and ICB Resistance: Time is on Tumor's Side
- PMID: 28718428
- DOI: 10.1016/j.trecan.2017.01.004
IFN Signaling and ICB Resistance: Time is on Tumor's Side
Abstract
Activation of antitumor immunity upon immune checkpoint blockade (ICB) is one of the most promising strategies in cancer therapy. However, ICB resistance is frequently observed in cancer preclinical models and patients. A recent report in Cell reveals that sustained interferon (IFN) signaling confers tumor resistance to ICB by inducing the expression of an immunosuppressive multigenic program.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment on
-
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022. Cell. 2016. PMID: 27912061 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
